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To empirically determine a categorization of people who inject drug (PWIDs) recently 26 
infected with hepatitis C virus (HCV), in order to identify profiles most likely associated with 27 
early HCV treatment uptake. 28 
METHODS: 29 
The study population was composed of HIV-negative PWIDs with a documented recent 30 
HCV infection. Eligibility criteria included being 18 years old or over, and having injected drugs 31 
in the previous 6 months preceding the estimated date of HCV exposure. Participant 32 
classification was carried out using a TwoStep cluster analysis. 33 
RESULTS: 34 
From September 2007 to December 2011, 76 participants were included in the study. 60 35 
participants were eligible for HCV treatment. Twenty-one participants initiated HCV treatment. 36 
The cluster analysis yielded 4 classes: Class 1: Lukewarm health seekers dismissing HCV 37 
treatment offer; Class 2: Multi-substance users willing to shake off the hell; Class 3: PWIDs 38 
unlinked to health service use; Class 4: Health seeker PWIDs willing to reverse the fate. 39 
CONCLUSION: 40 
Profiles generated by our analysis suggest that prior health care utilization, a key element 41 
for treatment uptake, differ between older and younger PWIDs. Such profiles could inform the 42 
development of targeted strategies to improve health outcomes and reduce HCV infection among 43 
PWIDs.  44 
 45 
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INTRODUCTION 47 
The prevalence of HCV infection is estimated at 130-170 million people worldwide, 48 
currently driven by the growing number of infections among people who inject drugs (PWID).[1]  49 
Not treated, the majority (75-85%) evolve to chronic infection; and some (20%) develop 50 
intractable and lethal diseases (cirrhosis, liver failure, hepatoma).[2]  51 
Before the advent of well-tolerated, orally administered HCV treatment regimens, 52 
traditional interferon-based antiviral treatment induced significant side effects that were deterring 53 
some patients from completing the treatment course.  For patients who achieved sustained viral 54 
response equivalent to a cure, HCV treatment was shown to bring additional benefits, such as 55 
reduction of risky drug-consumption behaviours,[3] and improvement of quality of life.[4] It is 56 
likely that within the next three to five years, well-tolerated, orally administered Interferon-free 57 
regimens will be available, thus improving the feasibility of treating difficult populations.[5] A 58 
recent modeling study by Martin and colleagues suggested that significant decreases in HCV 59 
prevalence can be accomplished by increasing simultaneously needle exchange program and 60 
opiate substitution therapy coverage on the one hand, and HCV treatment coverage on the other 61 
hand.[6] In large observational community-based drug users’ cohorts, however, the HCV 62 
treatment uptake was estimated at < 8%, or less than 1% annually.[7] Further, despite increasing 63 
efforts to attract vulnerable population in treatment, the number of PWIDs treated annually still 64 
stagnates.[8] 65 
Barriers to HCV treatment were found to be multi-factorial and included factors impeding 66 
optimal access at the level of the patient, system and practitioner.[7] Attempts to frame the 67 
influence of multidimensional factors and conditions facilitating or impeding health care access 68 
and outcomes can be guided by the Behavioral Model of Health Services Utilization, a 69 
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conceptual framework developed by Andersen and colleagues.[9]  Reasons cited by PWIDs with 70 
HCV for not seeking treatment include poor education about their condition and its treatment, an 71 
absence of noticeable symptoms, fear of adverse effects of treatment, and other ongoing medical 72 
comorbidities and social issues.[10] Beyond individual barriers, factors affecting treatment 73 
uptake include financial coverage, housing stability and assessment by the physician of the risks 74 
and benefits of immediate versus delayed treatment for HCV-chronically infected individuals.[7]  75 
From a service development perspective, it is important to identify profiles of individuals 76 
according to treatment uptake.  Such profiles could help inform novel interventions to increase 77 
treatment uptake in subgroups with specific characteristics.  PWIDs recently infected by HCV 78 
who are systematically offered treatment under universal financial coverage represent a unique 79 
group to study in order to assess how individual profiles, as opposed to specific risk factors, 80 
affect treatment uptake.  Cluster analysis have been used in intervention research to unmask 81 
unknown heterogeneity between concurrent groups by focusing more on inherent differences 82 
between cases than on individual variables.[11] 83 
The objective of this study was to empirically identify profiles associated with early HCV 84 
treatment uptake among recently HCV infected PWIDs who were systematically offered HCV 85 
treatment and were covered by universal health insurance.  86 
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METHODS 87 
A. STUDY POPULATION: 88 
  The study population was composed of PWIDs recently infected with HCV, enrolled in 89 
IMPACT, a study aimed at examining the effect of acute HCV infection and antiviral treatment 90 
on the behaviors and quality of life of PWIDs who have access to specific targeted health 91 
services. Eligibility criteria included being 18 years old or over, having injected drugs in the 92 
previous 6 months or in the 3 month-period preceding the estimated date of HCV infection, and 93 
living in the Greater Montreal area. Documented acute HCV infection was defined as either: 1) a 94 
HCV antibody negative test, followed by either an HCV antibody or RNA positive test within 6 95 
months of the HCV antibody negative test period; or 2) acute symptomatic infection with 96 
evidence of hepatitis illness (i.e. jaundice or alanine aminotransferase (ALT) elevation over 400 97 
U/L). Participants were recruited from two main sources: i) the St. Luc Cohort, a prospective 98 
cohort study with semi-annual visits designed to examine individual and contextual factors 99 
associated with HCV and HIV infections among current IDUs (i.e.: drug injection in the six 100 
months prior to recruitment);[12]; ii) community and hospital-based collaborating clinics, 101 
including the addiction medicine clinic at the Centre Hospitalier de l’Université de Montréal 102 
(CHUM).   103 
  Eligible individuals were invited to participate in the study and were systematically 104 
referred to the CHUM addiction medicine clinic for clinical assessment. PWIDs recently infected 105 
with HCV, who did not resolve spontaneously after 20 weeks of estimated infection, were 106 
offered HCV treatment regardless of their drug use or social conditions.  107 
The research protocol has been approved by the Institutional Research Ethical Board of 108 
the CHUM, and includes an authorization to access participants’ clinical data, when available. A 109 
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$30 stipend for travel costs was offered for each completed research visit. 110 
B. VARIABLES AND MEASUREMENT INSTRUMENTS: 111 
The variable of interest was “treatment initiation”, defined as receiving a first dose of 112 
Pegylated interferon. Information was retrieved from the clinical chart, and validated with the 113 
clinical nurse. Two measurement instruments were used to characterize participants. The SF-36 114 
questionnaire was used to assess health related quality of life (QualityMetric Health Outcomes™ 115 
Scoring Software 4.0). This questionnaire has been extensively used and validated in various 116 
patient settings as well as in the general population.[13] Using factor analysis, items of this 117 
questionnaire are conceptually reduced to two main dimensions: physical and mental component 118 
of quality of life, which were used for analysis in this study. A short interviewer-administered 119 
questionnaire, derived from the St. Luc Cohort questionnaire,[14] was used to collect socio-120 
demographic characteristics, information on injection drug use practices, health related factors 121 
and service utilization. Drug use consumption was documented for the prior 6 months. 122 
Given the focus on healthcare utilization, the sample has been described according to the 123 
Andersen model, with variables categorized as predisposing, enabling and need factors.[9] 124 
Predisposing factors comprise individual variables associated with service utilization. Enabling 125 
factors include contextual, systemic or structural variables associated with service utilization. 126 
Need factors relate to diseases or risky behaviors that could impact on health and wellbeing. 127 
Variables considered in our model were further chosen with respect to the current body of 128 
knowledge on HCV treatment access for drug users. 129 
C. ANALYSES: 130 
Frequency distribution for categorical variables and mean values along with standard 131 
deviations for continuous variables were used for descriptive analyses. Bivariate analyses using 132 
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Pearson Chi-square statistics for categorical variables and independent sample t-test for 133 
continuous variables were conducted to compare PWID characteristics according to HCV 134 
treatment initiation. Statistically significant differences were assessed at P <0.05; P-values were 135 
two-sided. 136 
Participant profile was carried out by means of a TwoStep cluster analysis using SPSS 137 
Statistics 20.0 package.[15, 16] Variables were introduced in the cluster analysis in an orderly 138 
manner, categorical variables first, and then continuous variables. The first categorical variable 139 
entered was “Having initiated HCV treatment”. Age categories and housing categories were 140 
multi-categorical variables. The SF-36 physical and mental component scores were entered as 141 
continuous scores in the model. The Log-likelihood method was used to determine inter-subject 142 
distance. The first iteration yielded a two-class cluster model based on Schwarz Bayesian criteria 143 
and Log-likelihood method, reflecting the overall contribution of participants to the inter-class 144 
homogeneity. This cluster analysis was discarded because classes were not contrasted enough for 145 
interpretation.[17] Finally the number of classes was set at 4 and produced an acceptable model. 146 
The quality of the model was estimated as satisfactory by the class cohesion and separation test. 147 
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RESULTS 148 
From September 2007 to December 2011, 76 participants infected with HCV within the 149 
previous six months were recruited in Montreal, Canada.  Sixteen (21%) cleared their infection 150 
spontaneously and were not included in this investigation. Table 1 presents descriptive 151 
characteristics of the 60 participants included in analyses, along with comparison analyses 152 
between those who have initiated HCV treatment and those who have not. Overall, 21 153 
participants (35%) had initiated HCV treatment. 154 
The four-class cluster analysis is displayed on Table 2. Classes were labelled according to 155 
the most prominent characteristics within classes. The four classes can be described as follow.  156 
Class 1: Lukewarm health seekers dismissing HCV treatment offer: Younger participants (79% 157 
under 30 y.o.), mostly females (86%), poorly educated (93% without a college degree), living 158 
predominantly in stable housing (64%). Compared to other classes, they rank fourth as to cocaine 159 
injection (64%), and second as to heroin injection. They have the lowest score on both physical 160 
and mental components of Quality of life. They represent one of the two highest proportions of 161 
participants followed-up by a family physician (35%), and the third lowest proportion of HCV 162 
treatment uptake (14%). 163 
Class 2: Multi-substance users willing to shake off the hell: mostly younger participants (87% 164 
under 30 y.o), exclusively males, poorly educated, living mostly in stable housing. All members 165 
(100%) of this class use IV cocaine and IV heroin. They rank first as regard alcohol 166 
consumption, and have the highest proportion of methadone program involvement. 53% have 167 
initiated a HCV treatment, ranking second of the 4 classes. 168 
Class 3:  PWIDs unlinked to health service use: Middle-age participants (64% between 30 and 169 
40 y.o.), exclusively males, with the highest proportion of homelessness of all classes, injecting 170 
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mostly cocaine. They also report the lowest involvement in health service use. No one in that 171 
class has initiated a HCV treatment.   172 
Class 4: Health seeker PWIDs willing to reverse the fate: The oldest group (all over 30 y. o.), 173 
mostly males, poorly educated, living predominantly (90%) in unstable housing conditions, and 174 
using IV cocaine use. Participants in this class have the highest score on the physical component 175 
of Quality of life, the highest proportion of heath service use and the highest proportion of HCV 176 
treatment initiation.  177 
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DISCUSSION 178 
PWIDs face many challenges and experience competing needs when it comes to taking 179 
care of their health.  Overall, 35% of eligible PWIDs initiated treatment.  The proportion of 180 
participants treated in our study soon after diagnosis is greater that in most studies among HCV 181 
infected active PWIDs.[18] This may indicate that delaying treatment, either for recently or 182 
chronically infected individuals, might not be the best option to increase uptake. Findings from a 183 
recent clinical trial conducted in Canada support this assumption: a higher overall sustained viral 184 
response (65% vs. 39%) was found among PWIDs allocated to immediate versus delayed 185 
treatment onset.[19] 186 
This study was undertaken to draw profiles associated with HCV treatment uptake after 187 
recent infection, in a setting where treatment was systematically offered under universal health 188 
insurance coverage. Overall, results suggest that educated male and female PWIDs, and those 189 
who had links with various health care services, as shown by prior hepatitis B vaccination, 190 
Opiate Substitution Treatment (OST) participation and visit to a health care professional, were 191 
more likely to initiate HCV treatment after recent infection, regardless of drug consumption. As 192 
in McGowan study,[20] participants in class 2 and 4, who initiated treatment, were also 193 
characterized by lower self-rated mental health quality of life. According to Anderson’s model, 194 
prior healthcare service utilization may enable further health service use.[9] Participants in class 195 
2 and 4, which together comprise 90% of all participants treated, had higher proportions of 196 
methadone program participation, hepatitis B vaccination and follow-up by family physician. In 197 
a study conducted in Australia by Digiusto and colleagues,[21] participants who had consulted a 198 
general practitioner for medication were more likely to have initiated HCV treatment. 199 
Participation to a methadone maintenance treatment has been associated with a higher 200 
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willingness to be treated,[22] to increased treatment uptake [23] and to better outcomes.[24] In a 201 
recent study among drug users followed in methadone and community clinics with enhanced 202 
HCV treatment access, methadone was not associated with uptake.[25] 203 
A salient characteristic of this cluster analysis was the identification of distinct profiles 204 
according to treatment uptake, for which standard comparisons were not quite informative.  For 205 
instance, age was not statistically associated with treatment uptake in bivariate analysis. 206 
However, the age distribution in clusters suggests that uptake profiles differ between older and 207 
younger drug users.  Class 1 and 2 comprised 24 of the 28 individuals under 30.  In contrast, 208 
class 3 and 4 included all but five individuals over 30.   209 
Hence, when contrasting “younger” (class 1 and 2) and “older” (class 3 and 4) PWID 210 
profiles, results from the cluster analysis suggest that the effect of health care utilization, an 211 
important element for treatment uptake, differed between older and younger groups. Younger 212 
individuals who initiated treatment reported being in methadone substitution treatment in higher 213 
proportions. Vaccination and family physician attendance was reported by a substantial 214 
proportion of older individuals initiating treatment, and by none of those who did not.  In 215 
addition, class profiles showed that housing status, namely living in a prison, a shelter or in a 216 
therapy setting, was related to treatment uptake among older PWIDs, but not so among younger 217 
drug users. 218 
The seemingly positive impact of living in an institutional facility, either prison, therapy 219 
or shelter, on treatment uptake among older participants in our study may indicate enhanced 220 
linkages with healthcare services through service providers, relative to other individuals in this 221 
cohort.[26] Conversely, class 3 profile includes a majority of homeless individuals, no one 222 
having initiated HCV treatment. According to Andersen’s theory, when healthcare access is 223 
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determined by enabling factors, such as their housing situation among older participants, 224 
systemic inequity is an issue.[9] 225 
Active use of illicit drugs is a treatment barrier documented in many studies. Active illicit 226 
drug use was associated with reluctance to initiate HCV treatment by the patient,[27] as well as 227 
by the physician.[28] Alcohol abuse was also found associated with not initiating treatment.[29] 228 
In our setting, however, the proportion of participants reporting drug and alcohol use was slightly 229 
higher among initiates relative to participants who were not treated, consistent across all classes.  230 
Active substance use was not a motive to deny treatment in this study. This finding suggests that 231 
active drug use may not be an important factor in the decision to get treated in the absence of 232 
systemic and practitioner-level barriers. It is also possible that ongoing drug use was linked to 233 
more contact with health services, probably due to multiple health related consequences of drug 234 
use overtime. 235 
Results of this study are subject to numerous limitations. First, we acknowledge that our 236 
sample may not be representative of drug users in other settings. If there has been some observed 237 
shifts in its use, cocaine is still the most prevalent injection drug used in Eastern Canada.[30]  238 
Moreover, cocaine use worldwide has remained stable, with indications of increases in Oceania, 239 
Asia, Africa and some countries in South America.[31] Despite close clinical follow-up of 240 
participants through laboratory analyses, our results could be biased by the self-reported 241 
behavioral data related to alcohol and drug use. In general, self-reported data from PWIDs tend 242 
to be accurate.[32] This study could also be subject to interviewer bias, which has been 243 
mitigated, if not prevented, by regular retraining of interviewers to uphold the integrity of data 244 
collection procedures and avoid imposition of systematic bias. A sample of 60 participants is 245 
obviously low. Nonetheless, the quality of the model was estimated to be satisfactory.  246 
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CONCLUSION 247 
This study underscores the importance of reaching beyond the individual-level factors in 248 
characterizing vulnerable populations in relation to HCV treatment uptake. Looking at profiles 249 
instead of individual variables can help tackle health related behaviors of PWIDs recently 250 
infected with HCV. This natural experiment represents a novel approach to understanding how 251 
specific patient characteristics can be used to develop targeted strategies to improve health 252 
outcomes and reduce HCV infection. For example, systemic barriers should be recognized early 253 
among those eligible for HCV treatment - such as difficulty to access decent accommodation or 254 
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Table 1.  Characteristics of participants and comparative analyses according to treatment initiation 
(n=60) 
    Frequency distribution Comparison tests 
    Total sample 
(N = 60) 
Treatment  
not initiated  
n = 39 (65%) 
Treatment  
initiated  
n = 21 (35%) 
P value* 
  n % n % n %   
<30 y.o. 28 46,7 21 53,8 7 33,3   
30-39 y.o. 15 25,0 9 23,1 6 28,6 0.311 
Age 
categories  
>40 y.o. 17 28,3 9 23,1 8 38,1 0.133 
Female 15 25,0 11 28,2 4 19,0 0.437 Gender   
Male 45 75,0 28 71,8 17 81,0   
Education  Secondary or less 44 73,3 30 76,9 14 66,7 0.397 








22 36,7 12 30,8 10 47,6 0.217 
Housing  
Homeless 13 21,7 9 23,1 4 19,0 0.858 
Alcohol consumption  36 60,0 23 59,0 13 61,9 0.825 
 20 
IV Heroine   29 48,3 19 48,7 10 47,6 0.935 IV drugs 
consumed  IV Cocaine   53 88,3 34 87,2 19 90,5 0.705 
Vaccines 
received   
Hepatitis B Vaccine 17 28,3 7 17,9 10 47,6 0.015 
PCS Mean (SD) 46,4 10,2 45,6 9,8 47,9 10,9 0.389 Quality of 
life scores   MCS Mean (SD) 33,9 13,9 34,0 14,2 33,9 13,8 0.985 
Methadone  20 33,3 10 25,6 10 47,6 0.085 
Having been followed-up in the 
6 prior months by a family 
physician  
11 18,3 6 15,4 5 23,8 0.424 




Table 2.  Participants typology (cluster analysis; N= 60) 
  Class 1 
n = 14; 
(23.3%)  
Class 2 
n = 15; 
(25.0%)  
Class 3 
n = 11; 
(18.3%)  
Class 4 
n = 20; 
(33.3%)  
Combined 
N = 60; 
(100.0%)  
<30 y.o. 11 (78.6) 13 (86.7) 4 (36.4) 0 (0.0) 28 (46.7) 
30-39 y.o. 3 (21.4) 2 (13.3) 7 (63.6) 3 (15.0) 15 (25.0) 
Age  
categories  
n (%)  40 y.o. and over 0 (0.0) 0 (0.0) 0 (0.0) 17 (85.0) 17 (28.3) 
Females 12 (85.7) 0 (0.0) 0 (0.0) 3 (15.0) 15 (25.0) Gender  
n (%)  Males 2 (14.3) 15 (100.0) 11 (100.0) 17 (85.0) 45 (75.0) 
Elementary/secondary 13 (92.9) 12 (80.0) 6 (54.5) 13 (65.0) 44 (73.3) 
Predisposing 
factors   
Education  
n (%)  College or over 1 (7.1) 3 (20.0) 5 (45.5) 7 (35.0) 16 (26.7) 
Stable housing (home, 
apartment, room) 
9 (64.3) 9 (60.0) 5 (45.5) 2 (10.0) 25 (41.7) Enabling  
factor 
Housing  




4 (28.6) 2 (13.3) 0 (0.0) 16 (80.0) 22 (36.7) 
 22 
Homeless 1 (7.1) 4 (26.7) 6 (54.5) 2 (10.0) 13 (21.7) 
IV Cocaine consumption n (%)  9 (64.3) 15 (100.0) 11 (100.0) 18 (90.0) 53 (88.3) 
IV heroine consumption n (%)  9 (64.3) 15 (100.0) 2 (18.2) 3 (15.0) 29 (48.3) 
Alcohol consumption n (%)  8 (57.1) 13 (86.7) 4 (36.4) 11 (55.0) 36 (60.0) 
PCS Mean (SD) 45.7 (6.9) 46.4 (9.4) 46.7 (9.1) 46.8 (13.4) 46.4 (10.2) 
Need factors 
Quality of Life 
(SF-36)  
(Mean (SD)    




Methadone program n (%)  5 (35.7) 8 (53.3) 3 (27.3) 4 (20.0) 20 (33.3) 
 Hepatitis B Vaccine n (%)  4 (28.6) 3 (20.0) 0 (0.0) 10 (50.0) 17 (28.3) 
 Followed-up by a family physician n 
(%)    
5 (35.7) 1 (6.7) 0 (0.0) 5 (25.0) 11 (18.3) 
 Having initiated treatment  
n (%)  
2 (14.3) 8 (53.3) 0 (0.0) 11 (55.0) 21 (35.0) 
 
 
